Zevra Therapeutics, Inc. (ZVRA)

Zevra Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Revenue	27.46	10.16	28.65	13.29	12.84
Revenue Growth (YoY)	170.26%	-64.53%	115.61%	3.50%	-
Cost of Revenue	2.95	0.22	2.06	0	0
Gross Profit	24.52	9.94	26.59	13.29	12.84
Selling, General & Admin	34.31	15.04	8.7	7.92	10.82
Research & Development	39.81	19.8	10.16	8.84	19.42
Other Operating Expenses	0	17.66	0	2.13	2.95
Operating Expenses	74.12	52.5	18.86	18.9	33.18
Operating Income	-49.6	-42.57	7.73	-5.61	-20.34
Interest Expense / Income	1.5	0.34	0.23	4.79	4.86
Other Expense / Income	-5.06	-16.1	16.02	2.4	-0.65
Pretax Income	-46.05	-26.81	-8.52	-12.79	-24.54
Income Tax	0	-0.03	0.03	-0.03	-0.02
Net Income	-46.05	-26.77	-8.56	-12.76	-24.52
Preferred Dividends	0	0	54.34	0	0
Net Income Common	-46.05	-26.77	-62.9	-12.76	-24.52
Shares Outstanding (Basic)	35	34	30	4	2
Shares Outstanding (Diluted)	35	34	30	4	2
Shares Change	2.79%	15.87%	647.71%	114.79%	65.39%
EPS (Basic)	-1.30	-0.78	-2.11	-3.21	-13.23
EPS (Diluted)	-1.30	-0.78	-2.11	-3.21	-13.23
Free Cash Flow	-33.83	-18.81	10.34	-1.97	-23.76
Free Cash Flow Per Share	-0.95	-0.55	0.35	-0.49	-12.82
Gross Margin	89.28%	97.82%	92.81%	100.00%	100.00%
Operating Margin	-180.63%	-418.91%	26.98%	-42.21%	-158.40%
Profit Margin	-167.69%	-263.48%	-219.54%	-96.03%	-191.00%
Free Cash Flow Margin	-123.20%	-185.12%	36.08%	-14.84%	-185.08%
EBITDA	-43.54	-25.53	-8.04	-7.74	-19.38
EBITDA Margin	-158.56%	-251.22%	-28.06%	-58.22%	-150.96%
Depreciation & Amortization	1.01	0.94	0.26	0.27	0.3
EBIT	-44.55	-26.47	-8.3	-8.01	-19.69
EBIT Margin	-162.22%	-260.51%	-28.95%	-60.27%	-153.33%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).